ERBB2 and breast carcinoma: Further, the detection of breast cancer related biomarkers through genomic and transcriptomic analysis allows reclassification of the tumors into molecular subtypes3,4 such as Luminal A [ER+, PR+, and human epidermal growth factor 2 (HER2-)], Luminal B (low p53 mutation, ER+, PR+, and HER2++), Basal-like (Triple-negative), or HER2++ [Fig. 1(a)].